CommercialPrior AuthLow impact
Koselugo (selumetinib)
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Neurology, Pediatrics·Medical Policy
We identified it
Jun 20, 2026
Summary
The policy for Koselugo (selumetinib) has been updated to expand age eligibility from 1 year and older (previously 2-18 years) and clarify that drug samples cannot be used to satisfy prior authorization requirements. Prior authorization remains required for all patients with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.
Action Required
Immediately: Update prior authorization forms and billing system notes for Koselugo (selumetinib) to reflect expanded age eligibility (1 year and older, not 2-18 years). Ensure staff know that drug samples cannot be used to satisfy prior authorization requirements. Verify all NF1 patients with plexiform neurofibromas have proper prior auth before billing HCPCS J8499.